Syndax Pharmaceuticals Inc (SNDX)

On October 24, 2025, the FDA approved Revuforj (revumenib) for adult and pediatric patients with relapsed or refractory NPM1 mutated acute myeloid leukemia, but shares traded lower that day. On October 27, 2025, BTIG and HC Wainwright & Co. reiterated 'Buy' ratings with target prices of $56.00 and $40.00, respectively. On September 19, 2025, Syndax announced Revuforj's inclusion in the NCCN Clinical Practice Guidelines in Oncology for relapsed or refractory NPM1 mutated acute myeloid leukemia. Between September 4-10, 2025, several analysts initiated or reiterated "Buy" ratings for SNDX, including Guggenheim initiating coverage with a $34.00 price target, Goldman Sachs raising its price target from $20.00 to $24.00, and Stifel reinstating coverage with a $44.00 price target. On August 4, 2025, Syndax reported strong second-quarter 2025 financial results, exceeding expectations, with significant revenue growth for Revuforj and Niktimvo, and management increased its long-term market opportunity projections, leading to a 4.0% share gain the next day and a 27.8% increase in the subsequent 68 days. Overall, the share price declined by 22.70% between October 24, 2024, and October 23, 2025.

There is no explicit information available to indicate demand seasonality for Syndax Pharmaceuticals, Inc.'s products and services. The demand for pharmaceutical products, especially those for serious conditions like cancer, is typically driven by medical need and regulatory approvals rather than seasonal patterns.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases, operating within the Health Care sector. The company is dedicated to addressing unmet medical needs in oncology and immuno-oncology by developing therapies that target cancer cells and enhance the immune system's ability to fight tumors. Revuforj (revumenib) is a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), and is also being explored for metastatic colorectal cancer; it was approved by the FDA for adult and pediatric patients with relapsed or refractory NPM1 mutated acute myeloid leukemia on October 24, 2025, and previously approved for KMT2A-rearranged acute leukemia in late 2024. Niktimvo (axatilimab-csfr) is a colony-stimulating factor-1 receptor (CSF-1R) blocking antibody developed for the treatment of chronic graft-versus-host disease (cGVHD) and idiopathic pulmonary fibrosis, and was approved to treat cGVHD in the summer of 2024. Entinostat is an oral, small molecule, selective HDAC inhibitor currently in late-stage clinical trials for hormone receptor-positive breast cancer and other solid tumors, with Syndax having a licensing, development, and commercialization agreement with Eddingpharm International Company Limited.

Syndax Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts, and New York, New York, United States. The company's business activities are primarily conducted within the United States, and it aims for global market penetration through strategic partnerships and regulatory approvals.

Syndax Pharmaceuticals, Inc. has generally maintained a positive brand reputation in the past year, particularly within the analyst community, with a consensus "Strong Buy" rating. The FDA approvals of Revuforj for NPM1-mutated AML in October 2025 and KMT2A-rearranged acute leukemia in late 2024, along with the approval of Niktimvo for cGVHD in mid-2024, have significantly bolstered the company's standing. The inclusion of Revuforj in the NCCN Clinical Practice Guidelines in Oncology for R/R NPM1 Mutated AML in September 2025 enhances prescriber confidence and market access. Strong second-quarter 2025 financial results, with significant revenue growth for Revuforj and Niktimvo, and increased long-term market opportunity projections, highlight the effectiveness of the company's launch strategy and strong physician demand. Consistent "Buy" or "Strong Buy" ratings and positive price target adjustments from multiple analysts reflect confidence in the company's future performance and growth potential. While the stock price experienced a decline of 22.70% between October 2024 and October 2025, recent positive developments suggest an improving sentiment.

Syndax Pharmaceuticals, Inc. is primarily owned by institutional shareholders, with varying reported percentages (118.11%, 29.70% or 16.72%, and 105.49%), insiders holding 10.29% (or 1.37%), and retail investors holding 0.00% (or 68.93%). Major institutional owners include BlackRock, Inc., Kynam Capital Management, LP, Goldman Sachs Group Inc., Vanguard Group Inc., Eversept Partners, LP, Bank Of America Corp /de/, State Street Corp, StemPoint Capital LP, Franklin Resources Inc., and Point72 Asset Management, L.P. The largest individual shareholder is Luke Evnin, owning 2.17 million shares, representing 2.52% of the company.